Cargando…
Preparation of Fetal Bovine Serum–Copper Phosphate Hybrid Particles under Cell Culture Conditions for Cancer Cell Treatment
[Image: see text] Fetal bovine serum (FBS) particles, which mainly consist of bovine serum albumin, have the potential for biological and medical applications as drug carriers. The coacervation of albumin is a common technique for preparing albumin-based particles. The replacement of salt with novel...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404488/ https://www.ncbi.nlm.nih.gov/pubmed/36033705 http://dx.doi.org/10.1021/acsomega.2c04096 |
_version_ | 1784773651596312576 |
---|---|
author | Mochizuki, Chihiro Nakamura, Junna Nakamura, Michihiro |
author_facet | Mochizuki, Chihiro Nakamura, Junna Nakamura, Michihiro |
author_sort | Mochizuki, Chihiro |
collection | PubMed |
description | [Image: see text] Fetal bovine serum (FBS) particles, which mainly consist of bovine serum albumin, have the potential for biological and medical applications as drug carriers. The coacervation of albumin is a common technique for preparing albumin-based particles. The replacement of salt with novel metal salts such as Cu is an affordable way to embed the metal ion in the albumin-based particles. Further, increased Cu distribution is prevalent in many cancers. Here, we prepared adhesive cell-like FBS–copper phosphate hybrid particles [FBS-Cu(3)(PO(4))(2)], which exhibited toxicity toward cancer cells, with a narrow size distribution under cell culture conditions for preventing tumor progression. FBS-Cu(3)(PO(4))(2) showed peroxidase-like activity. In addition, FBS-Cu(3)(PO(4))(2) was successfully loaded with rhodamine B and conjugated with fluorescein isothiocyanate as models of drugs by coincubation. Thus, we designed a simple preparation method for optimizing FBS-Cu(3)(PO(4))(2) synthesis under cell culture conditions. FBS-Cu(3)(PO(4))(2) has significant potential as an efficient reactive oxygen species generator and drug-delivery agent against cancer cells. Furthermore, the RhoB-loaded FBS-Cu(3)(PO(4))(2) successfully interacted with 4T1 mouse mammary tumor cells and were confirmed to exhibit toxicity. |
format | Online Article Text |
id | pubmed-9404488 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-94044882022-08-26 Preparation of Fetal Bovine Serum–Copper Phosphate Hybrid Particles under Cell Culture Conditions for Cancer Cell Treatment Mochizuki, Chihiro Nakamura, Junna Nakamura, Michihiro ACS Omega [Image: see text] Fetal bovine serum (FBS) particles, which mainly consist of bovine serum albumin, have the potential for biological and medical applications as drug carriers. The coacervation of albumin is a common technique for preparing albumin-based particles. The replacement of salt with novel metal salts such as Cu is an affordable way to embed the metal ion in the albumin-based particles. Further, increased Cu distribution is prevalent in many cancers. Here, we prepared adhesive cell-like FBS–copper phosphate hybrid particles [FBS-Cu(3)(PO(4))(2)], which exhibited toxicity toward cancer cells, with a narrow size distribution under cell culture conditions for preventing tumor progression. FBS-Cu(3)(PO(4))(2) showed peroxidase-like activity. In addition, FBS-Cu(3)(PO(4))(2) was successfully loaded with rhodamine B and conjugated with fluorescein isothiocyanate as models of drugs by coincubation. Thus, we designed a simple preparation method for optimizing FBS-Cu(3)(PO(4))(2) synthesis under cell culture conditions. FBS-Cu(3)(PO(4))(2) has significant potential as an efficient reactive oxygen species generator and drug-delivery agent against cancer cells. Furthermore, the RhoB-loaded FBS-Cu(3)(PO(4))(2) successfully interacted with 4T1 mouse mammary tumor cells and were confirmed to exhibit toxicity. American Chemical Society 2022-08-12 /pmc/articles/PMC9404488/ /pubmed/36033705 http://dx.doi.org/10.1021/acsomega.2c04096 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Mochizuki, Chihiro Nakamura, Junna Nakamura, Michihiro Preparation of Fetal Bovine Serum–Copper Phosphate Hybrid Particles under Cell Culture Conditions for Cancer Cell Treatment |
title | Preparation of
Fetal Bovine Serum–Copper Phosphate
Hybrid Particles under Cell Culture Conditions for Cancer Cell Treatment |
title_full | Preparation of
Fetal Bovine Serum–Copper Phosphate
Hybrid Particles under Cell Culture Conditions for Cancer Cell Treatment |
title_fullStr | Preparation of
Fetal Bovine Serum–Copper Phosphate
Hybrid Particles under Cell Culture Conditions for Cancer Cell Treatment |
title_full_unstemmed | Preparation of
Fetal Bovine Serum–Copper Phosphate
Hybrid Particles under Cell Culture Conditions for Cancer Cell Treatment |
title_short | Preparation of
Fetal Bovine Serum–Copper Phosphate
Hybrid Particles under Cell Culture Conditions for Cancer Cell Treatment |
title_sort | preparation of
fetal bovine serum–copper phosphate
hybrid particles under cell culture conditions for cancer cell treatment |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404488/ https://www.ncbi.nlm.nih.gov/pubmed/36033705 http://dx.doi.org/10.1021/acsomega.2c04096 |
work_keys_str_mv | AT mochizukichihiro preparationoffetalbovineserumcopperphosphatehybridparticlesundercellcultureconditionsforcancercelltreatment AT nakamurajunna preparationoffetalbovineserumcopperphosphatehybridparticlesundercellcultureconditionsforcancercelltreatment AT nakamuramichihiro preparationoffetalbovineserumcopperphosphatehybridparticlesundercellcultureconditionsforcancercelltreatment |